Bioliberty

Executive Summary

Bioliberty is a UK-based medical device company developing a soft robotic glove for hand rehabilitation, powered by AI-guided exercises. The device targets conditions such as arthritis, stroke recovery, and age-related weakness, addressing a large and growing market for neurological and musculoskeletal rehabilitation. The company is currently in the preclinical stage, focusing on product development and initial validation. With an aging population and increasing prevalence of stroke and arthritis, Bioliberty's non-invasive, digital health solution could offer a scalable and cost-effective alternative to traditional physiotherapy. The company's key challenge will be demonstrating clinical efficacy and navigating regulatory pathways, particularly FDA or CE marking, to bring the product to market.

Upcoming Catalysts (preview)

• Q1 2027Initiation of First-in-Human Clinical Trial40% success
• Q4 2026Strategic Partnership or Licensing Deal with Rehabilitation Provider50% success
• Q3 2026Grant or Series A Funding Announcement60% success